

## Technical Data Sheet

### APC Conjugated Human CD30/TNFRSF8 Protein (C-His)

**Catalog Number:** 804703, 804704

**Size:** 25 ug, 100 ug

**Target Name:** TNFRSF8, CD30, Ki-1

**Regulatory Status:** RUO

#### Product Details

---

**Application:** FC

**Format:** Liquid, APC

**Expression Host:** CHO

**Species:** Human

**Sources:** Recombinant Human CD30 protein (phe19-Lys379) with C-terminus His tag is expressed in CHO cells and conjugated to APC.

**Accession Number:** P28908

**Molecular Weight:** The protein has a predicted molecular weight of 40 kDa. Under DTT-reducing conditions, it migrates at approximately 50-80 kDa on SDS-PAGE prior to conjugation.

**Affinity Tag:** C-His

**Formulation:** 1xPBS buffer, pH7.4, 0.09% NaN<sub>3</sub> with a carrier protein

**Endotoxin level:** Not tested

**Protein Concentration:** 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.

**Storage and Handling:** Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months.

#### Background Information

---

CD30, also known as TNFRSF8, is a 120 kDa type I transmembrane glycoprotein from the TNF receptor superfamily. It is expressed on activated T, B, and NK cells, but not resting cells. CD30 is cleaved by metalloproteinases into a soluble form and is highly expressed in classical Hodgkin lymphoma and anaplastic large cell lymphoma. It interacts with proteins like TRAF1, TRAF2, and TRAF5, activating NF-κB signaling. This signaling regulates the proliferative potential of autoreactive CD8 T cells and protects against autoimmunity. CD30 is a therapeutic target in lymphoma immunotherapy and plays a role in autoimmune diseases like rheumatoid arthritis.